Duzallo

RSS

allopurinol / lesinurad

Authorised
This medicine is authorised for use in the European Union.

Overview

An overview of Duzallo and why it is authorised in the EU

Duzallo is a medicine used in adults with gout to reduce high levels of uric acid in the blood. It is used when allopurinol on its own is not able to control uric acid levels sufficiently.

Gout results from a build-up of uric acid crystals in and around the joints, especially in the toes, which causes pain and swelling.

Duzallo contains the active substances allopurinol and lesinurad.

This EPAR was last updated on 24/08/2018

Authorisation details

Product details
Name
Duzallo
Agency product number
EMEA/H/C/004412
Active substance
  • allopurinol
  • lesinurad
International non-proprietary name (INN) or common name
allopurinol / lesinurad
Therapeutic area (MeSH)
Gout
Anatomical therapeutic chemical (ATC) code
M04AA51
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Grunenthal GmbH
Revision
0
Date of issue of marketing authorisation valid throughout the European Union
23/08/2018
Contact address
Zieglerstrasse 6
D-52078 Aachen
Germany

Product information

23/08/2018 Duzallo - EMEA/H/C/004412 - -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

ANTIGOUT PREPARATIONS

Therapeutic indication

Duzallo is indicated in adults for the treatment of hyperuricaemia in gout patients who have not achieved target serum uric acid levels with an adequate dose of allopurinol alone.

Assessment history

How useful was this page?

Add your rating